Risk of medication-related osteonecrosis of the jaw during romosozumab treatment
Main finding · MRONJResult — go to the resultHazard ratio 0.89 95% CI 0.39–2.01Authors' conclusion
These real-world data do not indicate a detectable excess short-term MRONJ risk with romosozumab compared with PTH analogs over the approved treatment window, although modest differences cannot be excluded because events were rare.
Study context
- Population
- Women aged ≥ 18 years with no prior osteonecrosis, jaw inflammatory disease, oral/head-neck cancer, or radiation exposure and no recent chemotherapy15,689 per cohort after matching
- Participants
- 15,689 vs 15,689
- Exposure
- Romosozumab vs parathyroid hormone (PTH) analogs in women
- Romosozumabn = 15,689
- PTH analogsn = 15,689reference
- Outcome
- Medication-related osteonecrosis of the jaw (MRONJ)
- Follow-up
- 1 year
Methodological detailsnew-user active comparator, propensity-score matched (1:1), TriNetX Global Collaborative Network
- New-user active comparator
- Propensity-score matched (1:1)
- TriNetX Global Collaborative Network
Main finding
MRONJ
Hazard ratio
0.89
95% CI 0.39–2.01
log-rank p = 0.78
Events by group
Romosozumabvs PTH analogs
HR 0.89 (95% CI 0.39–2.01); log-rank p = 0.78
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Hypercalcemia (positive control outcome) | 0.66 (0.58–0.75) | |
| 0.512Hazard ratio (log scale) |
Original publication
Risk of medication-related osteonecrosis of the jaw during romosozumab treatment. Osteoporos Int. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →